The study was performed in different populations and in much higher posology than recommended in the relevant core SPC because the Applicant considered that the indications, posology and pharmacokinetic information reported in the core SPC are not product specific, but rather that they apply to products complying with the relative European Pharmacopoeia monograph, such as UMAN BIG.